Skip to content
Telehealth Graded

Search Telehealth Graded

Use arrow keys or Tab to browse. Enter opens a result. Escape closes search.

Enter a name or topic to search.

Compounded supply

FDA warning letters to telehealth sellers in 2026

The FDA sent 55 warning letters to telehealth sellers over compounded semaglutide and tirzepatide marketing in 2026, by its own database's count: 30 letters dated February 20, announced on March 3, and 25 letters dated June 8. In 51 of 55, the FDA objected to a pictured vial label showing the seller's own name or logo, which suggests the seller makes the drug when it does not. 29 of the letters went to sellers we review, and each is listed below with what the FDA cited[1][3].

J. Merrick · Published · 32 sources · 7 min read

Educational content, not medical advice. Talk to a licensed clinician before starting any treatment.

What this comes down to

  • Two rounds: 30 letters dated February 20, 2026 and 25 letters dated June 8, 2026, all about compounded semaglutide, tirzepatide or both.
  • The most common finding, in 51 of 55 letters, is a vial pictured with the seller's name or logo. The FDA says that implies the seller is the compounder when it is not.
  • The rest are claims: "same active ingredient as Wegovy," "generic Zepbound," "clinically proven," and, in eleven letters, a pharmacy described as FDA-licensed or FDA-approved. The FDA licenses no pharmacy.
  • A warning letter is about what a seller's website said. It is not a recall, and it does not say a particular vial failed a test.
The FDA's 2026 warning letters to telehealth sellers
  • Dated February 20, 202630 letters
  • Dated June 8, 202625 letters
  • Objected to the seller's name on the vial label51 of 55
  • Sent to sellers we review29 of 55

Counted from each letter on the FDA's warning-letter database, searched for "telehealth" as the FDA advises.

What did the FDA announce on March 3, 2026?

“The U.S. Food and Drug Administration today announced the issuance of 30 warning letters to telehealth companies for making false or misleading claims regarding compounded GLP-1 products offered on their websites.”

[1]

The release names the two main problems: claims implying the compounded drug is the same as an FDA-approved one, and products branded with the telehealth company's name "without qualification, implying they are the compounder." It calls this the second group of warning letters to telehealth firms since the FDA began a crackdown on misleading drug ads in September 2025, and repeats that compounded drugs are not FDA-approved and are not the same as generics, which are[1]. Where these rules sit in the longer history of compounded GLP-1s is in the dated FDA timeline for compounded semaglutide.

A second round followed: 25 letters dated June 8, 2026, posted on June 16, 2026. The FDA's page for telehealth companies, current as of June 15, 2026, says it has issued warning letters to telehealth companies and tells readers to search its warning-letter database for "telehealth" to find them[2]. We ran that search and opened every 2026 letter it returned, 55 in all[3].

WhatFebruary roundJune round
Letters datedFebruary 20, 2026June 8, 2026
Letters3025
Posted on fda.govMarch 3, 2026 to March 5, 2026June 16, 2026
Websites reviewedDecember 2025March 2026 to May 2026
Seller's name or logo on the vial label3021
Pharmacy called FDA-licensed or FDA-approved011
Sent to sellers we review1514

The two 2026 rounds, counted from the letters themselves.

What violations do the letters cite?

The label finding comes first in 51 of 55 letters, in nearly the same words each time: the compounded products pictured on the website show the seller's name or logo on the label, "suggesting" the seller "is the compounder of those drugs when in fact it is not." A telehealth company arranges the prescription; a separate pharmacy makes the vial. The FDA treats a label that hides that as false or misleading.

Most letters then quote the website directly. The common lines are some version of "same active ingredient as Wegovy and Ozempic," "generic," "bioidentical," "clinically proven" or "FDA-approved." The FDA's answer is the same each time: compounded drugs are not FDA-approved, so a claim implying they were approved or evaluated for safety and effectiveness is false or misleading. In eleven letters, all from the June round, sellers also described their pharmacy as FDA-licensed or FDA-approved; the FDA says no such designation exists. Its telehealth page lists the same five things not to say[2].

What does a warning letter require the seller to do?

Each letter gives the seller 15 working days to reply in writing with the steps it has taken, and suggests three: name the entities that actually make the compounded products, send a sample of their labeling, and back up or remove the other claims. It warns that failing to fix the problems may lead to legal action, including seizure and injunction[16]. A letter is the FDA's notice about marketing. It is not a recall, and it does not say a vial failed a quality test.

Which sellers we review received a 2026 letter?

29 of the 55 letters are addressed to sellers we review. A seller is listed only when the letter is addressed to that brand; a similar name is not enough. Beside each name is what the letter cited; "a vial label showing its name" is the label finding above. Each name links to our review.

Letters dated February 20, 2026

  • Alan Meds: a vial label showing its name[4].
  • Belle Health: a vial label showing its name[5].
  • Bliv: a vial label showing its name[6].
  • FitRx: a vial label showing its name, and copy describing its semaglutide as the "active ingredient in Wegovy"[7].
  • Good Girl Rx: a vial label showing its name, and the claim "Clinically proven GLP-1 results"[8].
  • Ivim Health: a vial label showing its name[9].
  • Levity: a vial label showing its name, and the claim "The same ingredient as Ozempic® + Wegovy®"[10].
  • MaxLife: a vial label showing its name, a "generic compounded medication" claim, and copy saying the treatment was "clinically tested and FDA-approved"[11].
  • Measured: a vial label showing its name, and the claim "Same active ingredient in Ozempic and Wegovy"[12].
  • MEDVi: a vial label showing its name, and the claim "Same active ingredient as Wegovy® and Ozempic®"[13].
  • NewSelf: a vial label showing its name, and the claim "Same active ingredient as Ozempic® & Wegovy®"[14].
  • SkinnyRx: a vial label showing its name, and the claim "It contains the same active ingredient as FDA-approved medications"[15].
  • Strut Health: a vial label showing its name, and the claim "Generic Zepbound, Mounjaro"[16].
  • WeightCare: a vial label showing its name[17].
  • Zappy Health: a vial label showing its name, and calling its product "a proven medication"[18].

Letters dated June 8, 2026

  • altRX: a vial label showing its name, and the claim "GLP-1s are clinically proven medications"[19].
  • AM Rx: a vial label showing its name, and copy tying its semaglutide to "FDA-approved medications like Wegovy and Ozempic"[20].
  • DrMedHealth: the claims "Same active ingredient as Ozempic®" and "Same active ingredient as Mounjaro®"[21].
  • Eden: a vial label showing its name, and the claim that its drugs come from "FDA-licensed 503(a) outsourcing facilities"[22].
  • Fitish: a vial label showing its name, and the line "Tirzepatide is the active ingredient in Mounjaro® and Zepbound®"[23].
  • Harper Meds: a vial label showing its name, a "Same active ingredient as Ozempic™ & Wegovy™" claim, and "FDA-licensed 503A Outsourcing Facilities"[24].
  • Joi + Blokes: a vial label showing its name, and calling its semaglutide "bioidentical with more expensive brands"[25].
  • Maximus: the claims "Proven to lose weight effectively" and "FDA approved pharmacies"[26].
  • Mint Med: a vial label showing its name[27].
  • NativeMed: a vial label showing its logo, and the claim "The same active ingredient in Ozempic® and Wegovy®"[28].
  • NexLife: a vial label showing its name[29].
  • OrderlyMeds: a vial label showing its logo, and the claim "FDA-licensed pharmacy"[30].
  • Roen Rx: a vial label showing its name, and copy tying its semaglutide to "FDA-approved medications like Wegovy and Ozempic"[31].
  • VivioMD: a vial label showing its name[32].

The other 26 letters went to sellers we do not review. Every letter is on the FDA's database, searchable by company name[3].

How do you read a compounded GLP-1 sales page now?

  1. Find out who makes the vial. If the pictured label shows only the seller's brand, ask which pharmacy compounds it and look that pharmacy up. How to check a compounding pharmacy shows where.
  2. Read "generic" or "same as Wegovy" as a red flag. Generics are FDA-approved; compounded drugs are not[2].
  3. Read "FDA-approved" or "clinically proven" about a compounded product the same way. The approval and the trials belong to the brand.
  4. Read "FDA-licensed pharmacy" as wrong on its face. The FDA does not approve or license any pharmacy or outsourcing facility.
  5. Check the dose instructions add up before the first injection. Tirzepatide units to mg shows the arithmetic, and compounded tirzepatide in 2026 covers what is still legal.

Questions people actually ask

How many warning letters did the FDA send to telehealth companies in 2026?

55 letters dated in 2026 are on the FDA's warning-letter database under a "telehealth" search: 30 letters dated February 20, announced March 3, and 25 letters dated June 8. All concern compounded semaglutide, tirzepatide or both.

Why did the FDA send warning letters to telehealth companies?

For false or misleading marketing of compounded GLP-1s: vial labels showing the seller's name as if it made the drug, and claims that the products are generic, the same as Wegovy or Zepbound, FDA-approved, or made in FDA-licensed pharmacies.

Does a warning letter mean the medication is unsafe?

Not by itself. These letters are about what the seller's website claimed, not a test of a vial, and none is a recall. The FDA does say compounded drugs are not reviewed for safety, effectiveness or quality before sale. Ask your prescriber about your own treatment.

Is compounded semaglutide or tirzepatide the same as Wegovy or Zepbound?

No. It may use the same active ingredient, but it is not FDA-approved and is not a generic. The FDA cited "same active ingredient" and "generic" claims as false or misleading in its 2026 letters.

How can I check whether a seller got an FDA warning letter?

Search the FDA's warning-letter database for the company's name, or for "telehealth" as the FDA suggests. Read the letter's recipient line and the website it names, because different companies can use similar brand names.

Sources

Every source below was read for this article, with the claim it supports written beside it.

  1. 1.
    FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s. U.S. Food and Drug Administration, 2026. Source · Document dated March 2026
    On March 3, 2026 the FDA announced 30 warning letters to telehealth companies over false or misleading compounded GLP-1 claims; primary violations were sameness claims and seller-branded products implying the telehealth firm is the compounder; the second group of letters to telehealth firms since the September crackdown; compounded drugs are not FDA-approved and not the same as generics.
  2. 2.
    FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs. U.S. Food and Drug Administration, 2026. Source · Document dated June 2026
    The FDA has issued warning letters to telehealth companies and directs readers to search "telehealth" in its warning-letter database; it reminds telehealth companies not to imply they are the compounder, call a compounded drug generic or the same as an approved drug, claim FDA approval or clinical proof of the same result, or claim an FDA-approved or FDA-licensed pharmacy; the FDA does not approve or license any facility.
  3. 3.
    Warning Letters (searchable database). U.S. Food and Drug Administration, 2026. Source
    A full-text search for "telehealth" on October 5, 2026 returned 55 letters issued in 2026: 30 dated February 20 and 25 dated June 8. Each was opened; 51 object to a pictured vial label bearing the seller's name or logo, and 11 state that there is no FDA-approved or FDA-licensed pharmacy designation.
  4. 4.
    Warning Letter: Alan Health Technologies Inc. dba Alan, MARCS-CMS 721814. U.S. Food and Drug Administration, 2026. Source · Document dated February 2026
    Letter dated February 20, 2026 to Alan Health Technologies Inc. dba Alan after an FDA review of its website in December 2025; it cites a vial label showing its name.
  5. 5.
    Warning Letter: Belle Health LLC dba Belle, MARCS-CMS 721795. U.S. Food and Drug Administration, 2026. Source · Document dated February 2026
    Letter dated February 20, 2026 to Belle Health LLC dba Belle after an FDA review of its website in December 2025; it cites a vial label showing its name.
  6. 6.
    Warning Letter: Bliv Wellness LLC dba Bliv, MARCS-CMS 721479. U.S. Food and Drug Administration, 2026. Source · Document dated February 2026
    Letter dated February 20, 2026 to Bliv Wellness LLC dba Bliv after an FDA review of its website in December 2025; it cites a vial label showing its name.
  7. 7.
    Warning Letter: FitRX, LLC dba FitRx, MARCS-CMS 717987. U.S. Food and Drug Administration, 2026. Source · Document dated February 2026
    Letter dated February 20, 2026 to FitRX, LLC dba FitRx after an FDA review of its website in December 2025; it cites a vial label showing its name, and copy describing its semaglutide as the "active ingredient in Wegovy".
  8. 8.
    Warning Letter: Good Girl LLC dba GoodGirlRX, MARCS-CMS 721449. U.S. Food and Drug Administration, 2026. Source · Document dated February 2026
    Letter dated February 20, 2026 to Good Girl LLC dba GoodGirlRX after an FDA review of its website in December 2025; it cites a vial label showing its name, and the claim "Clinically proven GLP-1 results".
  9. 9.
    Warning Letter: Ivim Services LLC dba Ivim, MARCS-CMS 721816. U.S. Food and Drug Administration, 2026. Source · Document dated February 2026
    Letter dated February 20, 2026 to Ivim Services LLC dba Ivim after an FDA review of its website in December 2025; it cites a vial label showing its name.
  10. 10.
    Warning Letter: Levity Inc. dba Levity, MARCS-CMS 717990. U.S. Food and Drug Administration, 2026. Source · Document dated February 2026
    Letter dated February 20, 2026 to Levity Inc. dba Levity after an FDA review of its website in December 2025; it cites a vial label showing its name, and the claim "The same ingredient as Ozempic® + Wegovy®".
  11. 11.
    Warning Letter: MaxLife Technologies Inc. dba Maxlife, MARCS-CMS 721453. U.S. Food and Drug Administration, 2026. Source · Document dated February 2026
    Letter dated February 20, 2026 to MaxLife Technologies Inc. dba Maxlife after an FDA review of its website in December 2025; it cites a vial label showing its name, a "generic compounded medication" claim, and copy saying the treatment was "clinically tested and FDA-approved".
  12. 12.
    Warning Letter: Better Health Labs, Inc. dba Measured, MARCS-CMS 721454. U.S. Food and Drug Administration, 2026. Source · Document dated February 2026
    Letter dated February 20, 2026 to Better Health Labs, Inc. dba Measured after an FDA review of its website in December 2025; it cites a vial label showing its name, and the claim "Same active ingredient in Ozempic and Wegovy".
  13. 13.
    Warning Letter: MEDVi, LLC dba MEDVi, MARCS-CMS 721455. U.S. Food and Drug Administration, 2026. Source · Document dated February 2026
    Letter dated February 20, 2026 to MEDVi, LLC dba MEDVi after an FDA review of its website in December 2025; it cites a vial label showing its name, and the claim "Same active ingredient as Wegovy® and Ozempic®". Addressed to this brand: the letter's Newark, Delaware address is the one MEDVi's own site prints.
  14. 14.
    Warning Letter: NewSelf Limited dba NewSelf, MARCS-CMS 721472. U.S. Food and Drug Administration, 2026. Source · Document dated February 2026
    Letter dated February 20, 2026 to NewSelf Limited dba NewSelf after an FDA review of its website in December 2025; it cites a vial label showing its name, and the claim "Same active ingredient as Ozempic® & Wegovy®".
  15. 15.
    Warning Letter: Lean Rx, Inc. dba SkinnyRx, MARCS-CMS 717989. U.S. Food and Drug Administration, 2026. Source · Document dated February 2026
    Letter dated February 20, 2026 to Lean Rx, Inc. dba SkinnyRx after an FDA review of its website in December 2025; it cites a vial label showing its name, and the claim "It contains the same active ingredient as FDA-approved medications".
  16. 16.
    Warning Letter: Strut Health, LLC dba Strut, MARCS-CMS 721448. U.S. Food and Drug Administration, 2026. Source · Document dated February 2026
    Letter dated February 20, 2026 to Strut Health, LLC dba Strut after an FDA review of its website in December 2025; it cites a vial label showing its name, and the claim "Generic Zepbound, Mounjaro".
  17. 17.
    Warning Letter: Weightless Medical LLC dba WeightCare, MARCS-CMS 721478. U.S. Food and Drug Administration, 2026. Source · Document dated February 2026
    Letter dated February 20, 2026 to Weightless Medical LLC dba WeightCare after an FDA review of its website in December 2025; it cites a vial label showing its name.
  18. 18.
    Warning Letter: Kare Solutions, LLC dba Zappy, MARCS-CMS 717991. U.S. Food and Drug Administration, 2026. Source · Document dated February 2026
    Letter dated February 20, 2026 to Kare Solutions, LLC dba Zappy after an FDA review of its website in December 2025; it cites a vial label showing its name, and calling its product "a proven medication".
  19. 19.
    Warning Letter: Trinity HealthCare Supply, LLC dba altRx, MARCS-CMS 728236. U.S. Food and Drug Administration, 2026. Source · Document dated June 2026
    Letter dated June 8, 2026 to Trinity HealthCare Supply, LLC dba altRx after an FDA review of its website in May 2026; it cites a vial label showing its name, and the claim "GLP-1s are clinically proven medications".
  20. 20.
    Warning Letter: FitRX, LLC dba AM RX, MARCS-CMS 728275. U.S. Food and Drug Administration, 2026. Source · Document dated June 2026
    Letter dated June 8, 2026 to FitRX, LLC dba AM RX after an FDA review of its website in March 2026; it cites a vial label showing its name, and copy tying its semaglutide to "FDA-approved medications like Wegovy and Ozempic".
  21. 21.
    Warning Letter: Public Health Solution LLC dba DrMedHealth, MARCS-CMS 728278. U.S. Food and Drug Administration, 2026. Source · Document dated June 2026
    Letter dated June 8, 2026 to Public Health Solution LLC dba DrMedHealth after an FDA review of its website in March 2026; it cites the claims "Same active ingredient as Ozempic®" and "Same active ingredient as Mounjaro®".
  22. 22.
    Warning Letter: Eden Health International Inc. dba Eden, MARCS-CMS 728279. U.S. Food and Drug Administration, 2026. Source · Document dated June 2026
    Letter dated June 8, 2026 to Eden Health International Inc. dba Eden after an FDA review of its website in March 2026; it cites a vial label showing its name, and the claim that its drugs come from "FDA-licensed 503(a) outsourcing facilities". Addressed to this brand: Eden's own terms name Eden Health International Inc., the letter's addressee.
  23. 23.
    Warning Letter: FITISH, MARCS-CMS 728280. U.S. Food and Drug Administration, 2026. Source · Document dated June 2026
    Letter dated June 8, 2026 to FITISH after an FDA review of its website in March 2026; it cites a vial label showing its name, and the line "Tirzepatide is the active ingredient in Mounjaro® and Zepbound®".
  24. 24.
    Warning Letter: Nexus Health Solutions LLC dba Harper Meds, MARCS-CMS 728281. U.S. Food and Drug Administration, 2026. Source · Document dated June 2026
    Letter dated June 8, 2026 to Nexus Health Solutions LLC dba Harper Meds after an FDA review of its website in March 2026; it cites a vial label showing its name, a "Same active ingredient as Ozempic™ & Wegovy™" claim, and "FDA-licensed 503A Outsourcing Facilities".
  25. 25.
    Warning Letter: Joi and Blokes dba Joi + Blokes, MARCS-CMS 728283. U.S. Food and Drug Administration, 2026. Source · Document dated June 2026
    Letter dated June 8, 2026 to Joi and Blokes dba Joi + Blokes after an FDA review of its website in March 2026; it cites a vial label showing its name, and calling its semaglutide "bioidentical with more expensive brands".
  26. 26.
    Warning Letter: Maximus Health, Inc. dba Maximus, MARCS-CMS 730095. U.S. Food and Drug Administration, 2026. Source · Document dated June 2026
    Letter dated June 8, 2026 to Maximus Health, Inc. dba Maximus after an FDA review of its website in May 2026; it cites the claims "Proven to lose weight effectively" and "FDA approved pharmacies".
  27. 27.
    Warning Letter: Glow Medispa, LLC dba Mint Med, MARCS-CMS 730390. U.S. Food and Drug Administration, 2026. Source · Document dated June 2026
    Letter dated June 8, 2026 to Glow Medispa, LLC dba Mint Med after an FDA review of its website in May 2026; it cites a vial label showing its name.
  28. 28.
    Warning Letter: NativeMed LLC dba NativeMed, MARCS-CMS 728287. U.S. Food and Drug Administration, 2026. Source · Document dated June 2026
    Letter dated June 8, 2026 to NativeMed LLC dba NativeMed after an FDA review of its website in March 2026; it cites a vial label showing its logo, and the claim "The same active ingredient in Ozempic® and Wegovy®".
  29. 29.
    Warning Letter: Nexlife Inc. dba Nexlife, MARCS-CMS 730096. U.S. Food and Drug Administration, 2026. Source · Document dated June 2026
    Letter dated June 8, 2026 to Nexlife Inc. dba Nexlife after an FDA review of its website in March 2026; it cites a vial label showing its name.
  30. 30.
    Warning Letter: OrderlyMeds LLC dba OrderlyMeds, MARCS-CMS 728291. U.S. Food and Drug Administration, 2026. Source · Document dated June 2026
    Letter dated June 8, 2026 to OrderlyMeds LLC dba OrderlyMeds after an FDA review of its website in March 2026; it cites a vial label showing its logo, and the claim "FDA-licensed pharmacy".
  31. 31.
    Warning Letter: Roen Health, Inc. dba RoenRx, MARCS-CMS 728293. U.S. Food and Drug Administration, 2026. Source · Document dated June 2026
    Letter dated June 8, 2026 to Roen Health, Inc. dba RoenRx after an FDA review of its website in March 2026; it cites a vial label showing its name, and copy tying its semaglutide to "FDA-approved medications like Wegovy and Ozempic".
  32. 32.
    Warning Letter: VivioMD Group LLC dba VivioMD, MARCS-CMS 728295. U.S. Food and Drug Administration, 2026. Source · Document dated June 2026
    Letter dated June 8, 2026 to VivioMD Group LLC dba VivioMD after an FDA review of its website in March 2026; it cites a vial label showing its name.

Key figures

Warning letters dated in 2026
55
Objected to the seller's name on the vial label
51 of 55
Sent to sellers we review
29 of 55
Days to respond
15 working days